Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | DHODH | Q02127 | 7/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117405 | 0.87 | EPRS1 (0.71) | KDM4EHSD17B10ALDH1A1DHODHHIF1A | |
| SCHEMBL10552947 | 0.85 | DHODH (0.80) | KDM4ELMNASMN1; SMN2PDE10AALDH1A1 | |
| SCHEMBL26074001 | 0.84 | KDM4E (0.70) | KDM4ELMNASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL1897678 | 0.83 | POLB (0.73) | KDM4ELMNASMN1; SMN2PDE10AHSD17B10 | |
| SCHEMBL8312271 | 0.83 | MEN1 (0.53) | KDM4ELMNASMN1; SMN2PDE10AHSD17B10 | |
| Cinchophen SCHEMBL25519 | 0.82 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10AHSD17B10 | |
| Cinchophen SCHEMBL29376617 | 0.82 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10AHSD17B10 | |
| Cinchophen SCHEMBL7588217 | 0.82 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10AHSD17B10 | |
| SCHEMBL1903454 | 0.82 | DHODH (0.94) | KDM4ELMNASMN1; SMN2PDE10AHSD17B10 | |
| SCHEMBL1901337 | 0.82 | EPRS1 (0.77) | KDM4ELMNASMN1; SMN2PDE10AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
| CN-102099352-A | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INC ASS | 2011-06-15 | — | — | CN | disclosed |
| EP-2325181-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | Pharma Ip General Incorporated Association (JP) | 2011-05-25 | — | — | EP | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | KDM4E 532/4885LMNA 4766/4885SMN1; SMN2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.